|
|
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
Muthu Veeraputhiran, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA
|
|
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASH2009: Brian Durie, Bank On A Cure® Update
ASH2009: Gareth Morgan, Bank On A Cure® Update
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
What is multiple myeloma?
Dr. Morie Gertz of the Mayo Clinic in Rochester, MN.
ASCO 2010: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
ASCO 2010: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASCO 2010: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASCO 2010: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
ASCO 2010: Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.
A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
ASCO 2010: Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.
ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
ASCO 2010: Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
ASCO 2010: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
ASCO 2010: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
ASCO 2010: Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
ASCO 2010: Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.
ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
ASCO 2010: Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study.
ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
A Practical Guide to Achieving and Maintaining the Best Response to Lenalidomide in Multiple Myeloma: Roundtable Proceedings
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASH 2009: Bank On A Cure®
Clinically relevant end points and new drug approvals for myeloma
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Eliminating the complete response penalty from myeloma response criteria
ESAs not the culprit: More studies required
Genetic association with thalidomide mediated venous thrombotic events in myeloma indentified using targeted genotyping
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
Genetic polymorphisms of EPHX1, Gsk3 beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
Genomic variation in myeloma: design, content, and initial
application of the Bank On A Cure SNP Panel to detect associations
with progression-free survival
IMWG consensus statement on the role of vertebral augmentation in multiple myeloma
IMWG Criteria for the Diagnosis of Myeloma and Guidelines for the Diagnostic Work-Up of Myeloma
IMWG Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-Dose Chemotherapy with Autologous Stem Cell Transplantation
IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
IMWG Guidelines for the Use of Bisphosphonates in Myeloma
Inaugural Summit of the International Myeloma Working Group Lays the Groundwork for a Course Toward a Cure.
International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma
International Myeloma Working Group at ASH 2009
International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma1
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals
Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma
Osteonecrosis of the Jaw and Biphosphonates
RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
Use of Bisphosphonates in Multiple Myeloma: IMGW Response to Mayo Clinic Consensus Statement
IMWG Guidelines for Facilities and Services for the Management of Myeloma Patients
Common Symptoms Of Multiple Myeloma
Statement on the passing of Senator Kennedy
Advocacy Update - September 1, 2009
Advocacy Update - September 15, 2009
Overviews
|
|
|
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
Revlimid
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain |
|
|
|
|
Noopur Raje, MD
Massachusetts General Cancer Center
Boston, Massachusetts, USA |
|
|
|
|
Michel Attal, MD
Hôpital Purpan
Toulouse, France |
|
|
|
|
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington, U.S.A. |
|
|
|
|
Philip McCarthy, MD
Roswell Park Cancer Institute
Buffalo, New York, USA |
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
|
|
|
Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia, USA |
|
Thalomid
|
|
|
Frits Van Rhee, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA |
|
|
|
|
Philippe Moreau, MD
Hôpital de Nantes
Nantes, France
|
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
Velcade
|
|
|
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, California, USA |
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
|
Frits Van Rhee, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA |
|
|
|
|
|
Philippe Moreau, MD
Hôpital de Nantes
Nantes, France
|
|
|
|
|
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
|
|
|
Sundar Jagannath, MD
Mt. Sinai Medical Center
New York, New York, U.S.A. |
|
|
|
|
Douglas Joshua, MD
University of Sydney
Sydney, Australia |
|
New Agents
|
|
|
Donald Benson, MD
The Ohio State Comprehensive Cancer Center
Columbus, Ohio, USA |
|
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain |
|
|
|
|
|
Noopur Raje, MD
Massachusetts General Cancer Center
Boston, Massachusetts, USA |
|
|
|
|
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri, USA |
|
|
|
|
Saad Usmani, MD
University of Connecticut Health Center
Farmington, Connecticut, USA |
|
|
|
|
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York, USA |
|
|
|
|
|
Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia, USA |
|
|
|
|
|
Sundar Jagannath, MD
Mt. Sinai Medical Center
New York, New York, U.S.A. |
|
|
|
|
|
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington, U.S.A. |
|
|
|
|
|
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
Transplant
|
|
|
|
Michel Attal, MD
Hôpital Purpan
Toulouse, France |
|
|
|
|
David Seldin, MD
Boston University School of Medicine
Boston, Massachusetts, USA |
|
|
|
|
|
Muthu Veeraputhiran, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA |
|
|
|
|
|
Philippe Moreau, MD
Hôpital de Nantes
Nantes, France
|
|
|
|
|
|
Philip McCarthy, MD
Roswell Park Cancer Institute
Buffalo, New York, USA |
|
Relapsed/Refractory
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
|
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain |
|
|
|
|
|
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York, USA |
|
|
|
|
|
Noopur Raje, MD
Massachusetts General Cancer Center
Boston, Massachusetts, USA |
|
|
|
|
|
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri, USA |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
|
|
|
|
Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia, USA |
|
|
|
|
|
Sundar Jagannath, MD
Mt. Sinai Medical Center
New York, New York, U.S.A. |
|
|
|
|
|
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington, U.S.A. |
|
|
|
|
|
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA |
|
Others
|
|
|
Noopur Raje, MD
Massachusetts General Cancer Center
Boston, Massachusetts, USA |
|
|
|
|
Christoph Heuck, MD
Montefiore Medical Center
Bronx, New York, USA |
|
|
|
|
Gareth Morgan, MD
The Royal Marsden Hospital
London, England |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA |
|
|
back
button next to the volume control in the
lower right hand corner.
print
related videos
related articles